{
 "as_of": "2026-10-15",
 "publisher": "My Peptide Information",
 "license": "CC BY 4.0",
 "items": [
  {
   "date": "2026-10-15",
   "title": "CNN investigation on telehealth GLP-1 prescribing to people with eating disorders",
   "summary": "CNN published an investigation into telehealth GLP-1 prescribing to people with anorexia and other eating disorders.",
   "what_it_means": "A legitimate program screens for eating disorders before prescribing; an intake that never asks is a warning sign.",
   "sources": [
    {
     "url": "https://edition.cnn.com/2026/10/15/business/weight-loss-drugs-eating-disorders-impact-intl",
     "publisher": "CNN"
    }
   ],
   "confidence": "confirmed"
  },
  {
   "date": "2026-10-14",
   "title": "HHS and FDA send an interim access policy for compounded peptides to White House review",
   "summary": "The OIRA review list on reginfo.gov shows \"Interim Access Policy for Compounding Using Certain Peptides\" (HHS/FDA, RIN 0910-ZD94, stage Notice) received October 14, 2026 and pending review; no text is posted. Reuters reported the filing on October 15. The AP, citing two people, said the policy would let pharmacies make some popular peptides, including BPC-157. A Washington Post report on October 7 had described a temporary plan while new rules are written.",
   "what_it_means": "Nothing has changed yet. Until a policy is published, BPC-157 and similar peptides remain outside FDA's compounding categories.",
   "sources": [
    {
     "url": "https://www.reginfo.gov/public/do/eoDetails?rrid=1568964",
     "publisher": "OIRA, reginfo.gov"
    },
    {
     "url": "https://www.yahoo.com/news/politics/articles/us-fda-takes-step-change-213124893.html",
     "publisher": "Reuters via Yahoo News"
    },
    {
     "url": "https://www.adn.com/nation-world/2026/10/07/the-trump-administration-is-paving-way-for-temporary-sale-of-some-unapproved-peptides/",
     "publisher": "Washington Post via Anchorage Daily News, Oct 7"
    }
   ],
   "confidence": "confirmed (filing); reported (content)"
  },
  {
   "date": "2026-10-13",
   "title": "Walmart will cover Ozempic and Mounjaro for employees with type 2 diabetes in 2027, not for weight loss",
   "summary": "CNBC reported Walmart's 2027 benefits: Ozempic and Mounjaro at no cost for employees with type 2 diabetes. GLP-1s prescribed for weight loss are still not covered.",
   "what_it_means": "Employer coverage is moving for diabetes, not for weight loss; cash-pay remains the route for most weight-loss patients.",
   "sources": [
    {
     "url": "https://www.cnbc.com/2026/10/13/walmart-glp-1s-inhalers-insulin-employee-benefits.html",
     "publisher": "CNBC"
    }
   ],
   "confidence": "confirmed"
  },
  {
   "date": "2026-10-12",
   "title": "Ozari Health announces compounded tirzepatide at $125 and semaglutide at $86",
   "summary": "Ozari Health announced two plans, including \"Ozari One\" at $125 a month for tirzepatide and $86 for semaglutide at every dose.",
   "what_it_means": "This is a press announcement. Ozari is not in our price index until we can read the price on its own checkout pages.",
   "sources": [
    {
     "url": "https://finance.yahoo.com/healthcare/articles/ozari-health-expands-nationwide-glp-140000342.html",
     "publisher": "Yahoo Finance (press coverage)"
    }
   ],
   "confidence": "reported"
  },
  {
   "date": "2026-10-01",
   "title": "FDA updates its page on unapproved GLP-1 drugs: retatrutide and cagrilintide cannot be compounded",
   "summary": "FDA's \"Concerns with unapproved GLP-1 drugs used for weight loss\" page (current as of October 1, 2026) states that retatrutide and cagrilintide cannot be used in compounding under federal law and that multi-dose compounded GLP-1 vials should be discarded 28 days after first use.",
   "what_it_means": "Any \"retatrutide\" offered online is an unapproved drug. If you use a compounded multi-dose vial, date it when you first puncture it.",
   "sources": [
    {
     "url": "https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss",
     "publisher": "U.S. FDA"
    }
   ],
   "confidence": "confirmed"
  },
  {
   "date": "2026-10-01",
   "title": "Rhode Island Medicaid ends coverage of GLP-1s prescribed only for weight loss",
   "summary": "Rhode Island Medicaid plans stopped covering GLP-1s prescribed solely for weight loss from October 1, 2026, according to a plan notice to providers.",
   "what_it_means": "Rhode Island Medicaid members using a GLP-1 for weight loss need a cash-pay or brand self-pay route.",
   "sources": [
    {
     "url": "https://www.point32health.org/provider/coverage-glp-1s-tufts-health-ritogether-members-092026",
     "publisher": "Point32Health provider notice"
    }
   ],
   "confidence": "confirmed"
  },
  {
   "date": "2026-09-29",
   "title": "CMS: Medicare GLP-1 Bridge runs through December 31, 2027",
   "summary": "CMS's BALANCE model page says the Medicare GLP-1 Bridge ($50 copay for eligible Part D enrollees, which began July 1, 2026) is extended through December 31, 2027, and that BALANCE will not launch in Medicare in 2027.",
   "what_it_means": "Eligible Medicare Part D enrollees can keep the $50 copay through 2027; Medicare open enrollment runs October 15 to December 7.",
   "sources": [
    {
     "url": "https://www.cms.gov/priorities/innovation/innovation-models/balance",
     "publisher": "CMS"
    }
   ],
   "confidence": "confirmed"
  },
  {
   "date": "2026-09-29",
   "title": "Charges filed over a counterfeit Ozempic scheme",
   "summary": "FDA announced charges against two people accused of distributing counterfeit Ozempic sourced from China between 2023 and 2024. An indictment is an allegation only.",
   "what_it_means": "Buy brand GLP-1s only from licensed pharmacies, LillyDirect or NovoCare.",
   "sources": [
    {
     "url": "https://www.fda.gov/news-events/press-announcements/fda-investigation-leads-charges-against-two-indian-nationals-involved-transnational-counterfeit-drug",
     "publisher": "U.S. FDA"
    }
   ],
   "confidence": "confirmed"
  },
  {
   "date": "2026-09-24",
   "title": "FDA warns two websites selling unapproved injectable semaglutide",
   "summary": "Warning letters 737806 (dated September 23) and 737810 (dated September 24), posted October 6, went to websites selling \"Semanat\" and \"Semanext\" injectable semaglutide as unapproved, misbranded drugs.",
   "what_it_means": "\"Generic semaglutide\" sold online is not a legitimate low-cost option.",
   "sources": [
    {
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/online-generic-medicinewwwonlinegenericmedicinecom-737806-09232026",
     "publisher": "U.S. FDA (737806)"
    },
    {
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cheap-medicine-shopwwwcheapmedicineshopcom-737810-09242026",
     "publisher": "U.S. FDA (737810)"
    }
   ],
   "confidence": "confirmed"
  },
  {
   "date": "2026-09-21",
   "title": "Novo Nordisk: self-pay is now central to Wegovy in the U.S.",
   "summary": "At its Capital Markets Day, Novo Nordisk described U.S. self-pay and direct-to-patient sales as central to Wegovy, including the Wegovy pill.",
   "what_it_means": "Manufacturer-direct prices (Wegovy pill from $149) are now the benchmark for any compounded price.",
   "sources": [
    {
     "url": "https://www.novonordisk.com/content/dam/nncorp/global/en/investors/pdfs/capital-markets-day/2026/uso-operations-presentation-cmd-2026.pdf",
     "publisher": "Novo Nordisk Capital Markets Day 2026 (US operations presentation)"
    }
   ],
   "confidence": "confirmed"
  },
  {
   "date": "2026-09-18",
   "title": "FDA warning letter 738238 to Empower Pharmacy",
   "summary": "FDA's letter, dated September 18 and posted September 22, says Empower's tirzepatide-niacinamide and semaglutide-cyanocobalamin products \"appear to be essentially copies of FDA-approved semaglutide and tirzepatide products\", calls the claimed differences pretextual, and cites insanitary conditions in sterile production.",
   "what_it_means": "GLP-1 \"plus vitamin\" blends are not a safe harbour. Ask your program which pharmacy fills your prescription and whether it has changed.",
   "sources": [
    {
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharmacy-738238-09182026",
     "publisher": "U.S. FDA"
    }
   ],
   "confidence": "confirmed"
  },
  {
   "date": "2026-08-24",
   "title": "FDA warns five \"research use only\" peptide sellers",
   "summary": "Warning letters dated August 24 went to Peptide Partners (735063), Peak Performance Peptides (735127), Royal Peptides (734884), NuScience Peptides (733652) and Tex Peptides (735067). FDA called their tirzepatide, semaglutide, retatrutide, tesamorelin, SS-31 and PT-141 products unapproved new drugs and said the \"research use only\" labels did not change that.",
   "what_it_means": "A research-use disclaimer does not make a peptide legal or safe to inject.",
   "sources": [
    {
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/royal-peptides-llc-734884-08242026",
     "publisher": "U.S. FDA (734884)"
    },
    {
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peptide-partners-llc-735063-08242026",
     "publisher": "U.S. FDA (735063)"
    }
   ],
   "confidence": "confirmed"
  },
  {
   "date": "2026-08-01",
   "title": "Louisiana peptide law (Act 374) takes effect",
   "summary": "Louisiana SB 253, signed as Act 374, took effect August 1, 2026. Secondary summaries say it stops state licensing boards from disciplining prescribers who provide peptides from compliant 503A pharmacies or FDA-registered 503B outsourcers.",
   "what_it_means": "It protects Louisiana clinicians from state-board action; it does not change federal compounding status.",
   "sources": [
    {
     "url": "https://www.legis.la.gov/legis/BillInfo.aspx?i=250428",
     "publisher": "Louisiana State Legislature"
    }
   ],
   "confidence": "confirmed (status); reported (content)"
  },
  {
   "date": "2026-07-23",
   "title": "FDA's compounding advisory committee reviews seven peptides",
   "summary": "The Pharmacy Compounding Advisory Committee met July 23'24 on BPC-157, KPV, TB-500, MOTs-C, emideltide (DSIP), Semax and Epitalon. FDA staff proposed not adding BPC-157 or TB-500 to the 503A bulks list. A law-firm account reports the committee voted to recommend six of the seven (BPC-157, KPV and TB-500 each 8'6) and voted against DSIP.",
   "what_it_means": "A committee vote is advice. As of October 15, none of these peptides has been added to the bulks list.",
   "sources": [
    {
     "url": "https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026",
     "publisher": "U.S. FDA (meeting page)"
    },
    {
     "url": "https://www.mcdermottlaw.com/insights/bulk-list-bound-pcac-backs-majority-of-peptides-in-two-day-public-meeting/",
     "publisher": "McDermott Will & Schulte (vote counts)"
    }
   ],
   "confidence": "confirmed (meeting); reported (votes)"
  }
 ]
}